US patent awarded to Biognosys
A patent from ETH Zurich which is exclusively licensed to Biognosys was granted in the US. This patent enables Biognosys to protect a key process in high-content targeted proteomics experiments.
Biognosys announces that a core patent from ETH Zurich which is exclusively licensed to Biognosys was granted in the US (US8501421 B2) and the corresponding application is pending in Europe. The patent describes a method for efficient development of SRM/MRM assays using, for example, synthetic peptide libraries.
With increasing demand for quantitative multiplexed proteomics the development and validation of assays becomes a bottleneck. This patent enables Biognosys to protect a key process in high-content targeted proteomics experiments.
Biognosys’ “targeted proteomics” can quantify proteins from any biological sample with unbeatable precision and speed. The solution is based on a novel mass spectrometric technology that allows simultaneous measurement of thousands of proteins in one sample and subsequent storage of the full information in a digital protein map.
The revolutionary feature of Biognosys’ HRM-MS™ technology is that it allows quantifying proteins retrospectively. It means that one physical measurement of a sample is sufficient for any future analysis of proteins that were present in the sample. This innovative concept of a Digital Biobank will revolutionize clinical research and diagnostics. The company was founded in 2008 and is located in Schlieren.
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines